INmune Bio (INMB)
(Real Time Quote from BATS)
$10.76 USD
+0.14 (1.32%)
Updated Apr 25, 2024 03:08 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for INmune Bio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 30 | 26 | 29 | 12 | 8 |
Income After Depreciation & Amortization | -30 | -26 | -29 | -12 | -8 |
Non-Operating Income | 0 | -1 | -1 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -30 | -27 | -30 | -12 | -8 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | -27 | -30 | -12 | -8 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | -27 | -30 | -12 | -8 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -30 | -26 | -29 | -12 | -8 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -30 | -26 | -29 | -12 | -8 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 17.98 | 17.93 | 16.13 | 11.99 | 10.27 |
Diluted EPS Before Non-Recurring Items | -1.67 | -1.52 | -1.88 | -1.01 | -0.75 |
Diluted Net EPS (GAAP) | -1.67 | -1.52 | -1.88 | -1.01 | -0.75 |
Fiscal Year end for INmune Bio, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.03 | 0.04 | 0.05 | 0.04 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.03 | 0.04 | 0.05 | 0.04 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 8.41 | 8.58 | 6.46 | 6.46 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -8.38 | -8.54 | -6.41 | -6.42 |
Non-Operating Income | NA | -0.03 | -0.04 | -0.09 | -0.11 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -8.41 | -8.56 | -6.50 | -6.54 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -8.41 | -8.56 | -6.50 | -6.54 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -8.41 | -8.56 | -6.50 | -6.54 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 17.98 | 18.01 | 17.95 | 17.95 |
Diluted EPS Before Non-Recurring Items | NA | -0.47 | -0.48 | -0.36 | -0.36 |
Diluted Net EPS (GAAP) | NA | -0.47 | -0.48 | -0.36 | -0.36 |